跳转至内容
Merck
CN

C3118

CPNQ

≥98% (HPLC), solid

别名:

5-[4-(4-chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline, B2

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H17ClN4O3
化学文摘社编号:
分子量:
396.83
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

CPNQ, ≥98% (HPLC), solid

InChI key

KLNPVNZJCWIQSK-UHFFFAOYSA-N

SMILES string

[O-][N+](=O)c1ccc(N2CCN(CC2)C(=O)c3ccc(Cl)cc3)c4cccnc14

InChI

1S/C20H17ClN4O3/c21-15-5-3-14(4-6-15)20(26)24-12-10-23(11-13-24)17-7-8-18(25(27)28)19-16(17)2-1-9-22-19/h1-9H,10-13H2

assay

≥98% (HPLC)

form

solid

color

brown

solubility

H2O: insoluble <2 mg/mL
DMSO: >5 mg/mL

storage temp.

2-8°C

Quality Level

Biochem/physiol Actions

CPNQ is a promoter of polyQ and α-synuclein inclusion formation and rescuer of Htt proteosomal dysfunction and α-synuclein toxicity.
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.

Other Notes

Product is air sensitive.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Edin Husić et al.
Bioinformatics (Oxford, England), 35(5), 769-777 (2018-08-14)
Discovering the evolution of a tumor may help identify driver mutations and provide a more comprehensive view on the history of the tumor. Recent studies have tackled this problem using multiple samples sequenced from a tumor, and due to clinical
Xiaofen Liu et al.
The Journal of infection, 82(2), 207-215 (2021-01-17)
Polymyxin B is a last-line antibiotic for multidrug-resistant gram-negative bacterial infections. However, limited safety and pharmacokinetic information is available. We investigated the safety and pharmacokinetics of intravenous polymyxin B in healthy subjects. An open-label, single-dose clinical trial was conducted in
Muralidhar Tata et al.
PloS one, 11(1), e0147811-e0147811 (2016-01-29)
The opportunistic human pathogen Pseudomonas aeruginosa can thrive under microaerophilic to anaerobic conditions in the lungs of cystic fibrosis patients. RNASeq based comparative RNA profiling of the clinical isolate PA14 cultured in synthetic cystic fibrosis medium was performed after planktonic
John K Diep et al.
International journal of antimicrobial agents, 52(3), 365-371 (2018-05-29)
A number of companies manufacture polymyxin B using United States Pharmacopeia (USP) metrics, rather than chemical composition, to report biological activity. Given that polymyxin B contains several different components, it is unknown whether pharmacokinetic and pharmacodynamic variability exists between the
Chantal M Ferguson et al.
Molecular therapy. Nucleic acids, 21, 384-393 (2020-07-11)
RNA interference (RNAi) is a potent mechanism that silences mRNA and protein expression in all cells and tissue types. RNAi is known to exert many of its functional effects in the cytoplasm, and thus, the cellular localization of target mRNA

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持